PATENT CLAIM ANALYSIS

Application Number: 16112430
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["424", "248100"]

Abstract:
An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably comprises a whole cell  Mycobacterium , for example,  M. vaccae  or  M. obuense.

Claim (Index 2):
A method according to  claim 1 , wherein said method comprises administering a sub-therapeutic amount of said antibody or antigen binding fragment thereof.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 96.0
- Lexical Diversity: 1.47368
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15104890', '13396866', '15803193', '14400667', '15510414']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6965579183599415
- 35 USC 102 Novelty (BERT): 0.5801445402214083
- Combined Prediction Score: 0.6849165805460882
- Mean Citation Score: 312.557202
- Max Citation Score: 503.75232
- Similarity Product: 359.75481521896364

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test